[go: up one dir, main page]

WO2011038149A3 - Méthodes de traitement d'une inflammation - Google Patents

Méthodes de traitement d'une inflammation Download PDF

Info

Publication number
WO2011038149A3
WO2011038149A3 PCT/US2010/050047 US2010050047W WO2011038149A3 WO 2011038149 A3 WO2011038149 A3 WO 2011038149A3 US 2010050047 W US2010050047 W US 2010050047W WO 2011038149 A3 WO2011038149 A3 WO 2011038149A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mif
treating inflammation
cxcr2
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/050047
Other languages
English (en)
Other versions
WO2011038149A2 (fr
Inventor
Jurgen Bernhagen
Christian Weber
Benedikt Vollrath
Court Turner
Joshua Robert Schults
Alma Zernecke
Sergio Duron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carolus Therapeutics Inc
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Priority to EP10819481.2A priority Critical patent/EP2480579A4/fr
Priority to BR112012006468A priority patent/BR112012006468A2/pt
Priority to AU2010298249A priority patent/AU2010298249A1/en
Priority to CN2010800526286A priority patent/CN102725311A/zh
Priority to MX2012003514A priority patent/MX2012003514A/es
Priority to CA2773978A priority patent/CA2773978A1/fr
Priority to IN2423DEN2012 priority patent/IN2012DN02423A/en
Publication of WO2011038149A2 publication Critical patent/WO2011038149A2/fr
Publication of WO2011038149A3 publication Critical patent/WO2011038149A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne, dans certains modes de réalisation, des méthodes pour traiter un trouble à médiation assurée par le facteur d'inhibition de la migration (MIF). Dans certains modes de réalisation, la méthode consiste à administrer un agent qui inhibe (i) la liaison du MIF à CXCR2 et CXCR4 et/ou (ii) l'activation par le MIFde CXCR2 et CXCR4; (iii) la capacité du MIF à former un homomultimère; ou une combinaison de celles-ci.
PCT/US2010/050047 2009-09-23 2010-09-23 Méthodes de traitement d'une inflammation Ceased WO2011038149A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP10819481.2A EP2480579A4 (fr) 2009-09-23 2010-09-23 Méthodes de traitement d'une inflammation
BR112012006468A BR112012006468A2 (pt) 2009-09-23 2010-09-23 métodos de tratamento de inflamação
AU2010298249A AU2010298249A1 (en) 2009-09-23 2010-09-23 Methods of treating inflammation
CN2010800526286A CN102725311A (zh) 2009-09-23 2010-09-23 治疗发炎的方法
MX2012003514A MX2012003514A (es) 2009-09-23 2010-09-23 Metodos para tratamiento de inflamaciones.
CA2773978A CA2773978A1 (fr) 2009-09-23 2010-09-23 Methodes de traitement d'une inflammation
IN2423DEN2012 IN2012DN02423A (fr) 2009-09-23 2010-09-23

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US61/245,214 2009-09-23
US31903910P 2010-03-30 2010-03-30
US61/319,039 2010-03-30

Publications (2)

Publication Number Publication Date
WO2011038149A2 WO2011038149A2 (fr) 2011-03-31
WO2011038149A3 true WO2011038149A3 (fr) 2011-10-27

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/050047 Ceased WO2011038149A2 (fr) 2009-09-23 2010-09-23 Méthodes de traitement d'une inflammation

Country Status (9)

Country Link
EP (1) EP2480579A4 (fr)
KR (1) KR20120105429A (fr)
CN (1) CN102725311A (fr)
AU (1) AU2010298249A1 (fr)
BR (1) BR112012006468A2 (fr)
CA (1) CA2773978A1 (fr)
IN (1) IN2012DN02423A (fr)
MX (1) MX2012003514A (fr)
WO (1) WO2011038149A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526886A (ja) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20150140005A1 (en) * 2012-05-17 2015-05-21 Cyon Therapeutics Inc. Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
TW201605886A (zh) * 2013-11-14 2016-02-16 巴克斯特保健公司 作爲治療標靶的ｍｉｆ
CA3017345A1 (fr) 2016-03-11 2017-09-14 Ardea Biosciences, Inc. Inhibiteurs du cxcr-2 permettant de traiter des troubles associes a une arthropathie cristalline
CN112512574A (zh) 2018-06-05 2021-03-16 安济药业(美国)有限责任公司 治疗胰腺炎的组合物和方法
AU2019417313B2 (en) * 2018-12-26 2023-01-19 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
CN115996741A (zh) * 2020-03-11 2023-04-21 百欧林纳克斯有限公司 用于治疗急性呼吸窘迫综合征及病毒感染的cxcr4抑制剂
US20210338626A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (zh) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 多肽at03在治疗原发性胆汁性胆管炎药物中的应用
EP4378319A1 (fr) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprenant des peptides bioactifs
CN119318647A (zh) * 2024-08-14 2025-01-17 南方医科大学 Sb225002在制备治疗心肌梗死的药物中的应用、治疗心肌梗死的组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009149A1 (en) * 2002-02-27 2004-01-15 Altman John D. Multimeric binding complexes
US20040115193A1 (en) * 2002-03-01 2004-06-17 Immunomedics, Inc. Internalizing anti-CD-74 antibodies and methods of use
US20050176039A1 (en) * 2003-12-30 2005-08-11 Siegler Katherine M. Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
EP1724286A1 (fr) * 2005-05-17 2006-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Variante du polypeptide CD44, polynucléotides les codant, anticorps le liant, et procédé d'utilisation pour le diagnostic et le traitement des maladies inflammatoires
US20070071675A1 (en) * 2005-08-19 2007-03-29 Chengbin Wu Dual variable domain immunoglobulin and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526244A (ja) * 2008-03-20 2011-10-06 カロラス セラピューティクス， インク． 炎症の処置方法
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009149A1 (en) * 2002-02-27 2004-01-15 Altman John D. Multimeric binding complexes
US20040115193A1 (en) * 2002-03-01 2004-06-17 Immunomedics, Inc. Internalizing anti-CD-74 antibodies and methods of use
US20050176039A1 (en) * 2003-12-30 2005-08-11 Siegler Katherine M. Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
EP1724286A1 (fr) * 2005-05-17 2006-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Variante du polypeptide CD44, polynucléotides les codant, anticorps le liant, et procédé d'utilisation pour le diagnostic et le traitement des maladies inflammatoires
US20070071675A1 (en) * 2005-08-19 2007-03-29 Chengbin Wu Dual variable domain immunoglobulin and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2480579A4 *
VENKATA ET AL.: "Chemically programmed antibodies: Endothelin receptor targeting CovX-bodies", BIOORGANIC AND MEDICAL CHEMISTRY LETTERS, vol. 17, 2007, pages 501 - 506, XP008154000 *

Also Published As

Publication number Publication date
EP2480579A4 (fr) 2013-07-31
KR20120105429A (ko) 2012-09-25
CA2773978A1 (fr) 2011-03-31
IN2012DN02423A (fr) 2015-08-21
WO2011038149A2 (fr) 2011-03-31
EP2480579A2 (fr) 2012-08-01
AU2010298249A1 (en) 2012-04-19
MX2012003514A (es) 2012-04-19
BR112012006468A2 (pt) 2016-08-09
CN102725311A (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
WO2009117710A3 (fr) Procédés de traitement d'inflammations
WO2011038149A3 (fr) Méthodes de traitement d'une inflammation
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2010065491A3 (fr) Procédés de traitement de troubles inflammatoires
WO2010141417A3 (fr) Systèmes et méthodes d'altération de la fonction du tissu du muscle lisse
MX2022003132A (es) Composiciones de corticoesteroides administradas oralmente.
WO2008122049A3 (fr) Procédés et compositions pour la réduction des effets secondaires des traitements thérapeutiques
WO2010087964A3 (fr) Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés
WO2009109908A8 (fr) Procédés de traitement d'une douleur inflammatoire
WO2010062581A3 (fr) Composition botanique pour une réparation cutanée optimisée et utilisations associées
WO2007142752A3 (fr) Dispositifs médicaux implantables composites en biocéramique-polymère
WO2009109911A8 (fr) Procédés de traitement d'une douleur chronique
WO2010005524A3 (fr) Systèmes et procédés d’utilisation afférents dans le traitement des anévrismes aortiques abdominaux
WO2008057246A3 (fr) Procédé de traitement de troubles inflammatoires
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2008036206A3 (fr) Dispositifs médicaux implantables à base de composite copolymère-biocéramique
WO2007081879A3 (fr) Méthodes pour prévenir et traiter des métastases de cancer et des pertes osseuses associées à des métastases de cancer
WO2008017025A3 (fr) Thérapie combinée
WO2009080800A3 (fr) Méthode pour réduire le tour de taille par l'administration de bactéries du genre bifidobacterium
WO2009016488A3 (fr) Compositions comprenant des antidépresseurs tétracycliques pour le traitement d'un cancer et procédés apparentés
WO2011044523A3 (fr) Compositions et procédés destinés à traiter l'obésité
WO2009155070A3 (fr) Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques
WO2011019867A3 (fr) Suppléments diététiques et procédés permettant de traiter la douleur et l'inflammation
WO2011116245A3 (fr) Méthodes de traitement d'une inflammation
WO2008073317A3 (fr) Cytarabine pour le traitement du gliome

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080052628.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10819481

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2773978

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010819481

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2423/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012531036

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/003514

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010298249

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 201270349

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2010298249

Country of ref document: AU

Date of ref document: 20100923

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127010455

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012006468

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012006468

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120322